LAUSR

cal mast-cell stabilizers, topical corticosteroids and topical calcineurin inhibitors. Dose adjustment or even cessation of the causative drug may be required in severe cases. In conclusion, with the limited data, it appears that tralokinumab is fairly safe, with most cases of conjunctivitis being mild-to-moderate and self-resolving. However, it would be helpful in the future to elucidate causative factors leading to more severe ocular disease and development with our ophthalmology colleagues of robust treatment guidelines for ocular disease, especially conjunctivitis, for those on biologic agents for AD.